Stockscreener 앱 받기
0.6204
0.02%
-0.016
전일 마감가:
$0.6364
열려 있는:
$0.63
하루 거래량:
679.37K
Relative Volume:
0.30
시가총액:
$112.39M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-0.4249
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+5.37%
1개월 성능:
-26.33%
6개월 성능:
-54.22%
1년 성능:
-48.69%
1일 변동 폭
$0.6114
$0.65
1주일 범위
$0.5904
$0.6809
52주 변동 폭
$0.432
$1.928
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
0.625 | 112.39M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.01 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.73 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.57 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.84 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com
Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN
Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN
Sector Update: Health Care - TradingView
Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance
Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance
Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga
Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - MarketScreener
Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India
Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider
IL-2 ADding contenders in eczema strategy - BioWorld MedTech
Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada
Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times
Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia
Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com South Africa
Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com
Nektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf Of - GuruFocus
Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 MillionSEC Filing - MarketScreener
Nektar Therapeutics (NKTR) Files $300M Mixed Shelf - StreetInsider
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight - Yahoo Finance
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials - Investing.com
Petrelintide up front shatters biotech deal record - biocentury.com
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil - Insider Monkey
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Lelezard
Nektar Therapeutics to Present Autoimmune Disease Updates at HC Wainwright Conference | NKTR Stock News - Stock Titan
Oppenheimer Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - MSN
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript - MSN
Oppenheimer Upgrades Nektar Therapeutics (NKTR) - Nasdaq
NEKTAR THERAPEUTICS SEC 10-K Report - TradingView
Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer -March 14, 2025 at 02:54 pm EDT - Marketscreener.com
Oppenheimer Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Nektar stock upgraded at Oppenheimer (NKTR:NASDAQ) - Seeking Alpha
Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider.com
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) - Yahoo Finance
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 - Marketscreener.com
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oppenheimer raises NKTR stock to Outperform, sets $6 price target - Investing.com
Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
BTIG keeps Nektar stock Neutral with $4.00 target By Investing.com - Investing.com Australia
Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics - TipRanks
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.11%
자본화:
|
볼륨(24시간):